Drug Trial Radar · NCT00128297
Pamidronate Administration in Breast Cancer Patients With Bone Metastases
Last checked: Nov 20, 2026Latest source record: Mar 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
152
Actual
Start
Oct 18, 2000
Primary completion
Jun 4, 2004
Study completion Jun 4, 2004
Sponsor
- Lead sponsor
- Spanish Breast Cancer Research GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novartis
- First posted
- Aug 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study objective is to evaluate the differences, in terms of first occurrence of a skeletal event, in patients with breast cancer and symptomatic bone metastases, when pamidronate is administered during 2 years, or when it is administered during 6 months, followed by a six month rest period, and again a 6 month treatment period.
Conditions
- Breast Cancer
- Neoplasm Metastasis
Interventions
PamidronateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pamidronate efficacy to prevent first skeletal event: time until the appearance of the first skeletal eventTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Spanish Breast Cancer Research Group (GEICAM)
San Sebastián de los Reyes, Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.